Icddr,b begins research on typhoid conjugate vaccine prevention

Bangladesh Sangbad Sangstha . Dhaka | Published: 01:28, Apr 16,2018 | Updated: 01:35, Apr 16,2018

 
 

Icddr,b in collaboration with Dhaka North City Corporation and Expanded Programme on Immunisation of Bangladesh has commenced a typhoid conjugate vaccine effectiveness study among 43,350 children from 9 months to 16 years, living in Mirpur, Dhaka.
The study is a part of the Typhoid Vaccine Acceleration Consortium project, in which researchers are conducting studies to evaluate just how much typhoid can be prevented by the typhoid conjugate vaccine in Bangladesh. Studies are also ongoing in Malawi and Nepal, said a press release.
Typhoid fever is caused by a bacterium, ‘Salmonella Enterica Serovar Typhi’ and is a major cause of illness, children and adolescents are mostly affected.
Globally, about one hundred and fifty thousand patients die due to typhoid every year but it causes severe illness in others.
Earlier studies have confirmed bacteremic typhoid fever incidence of 3.9 episodes per 1,000 person-years during fever surveillance in a Dhaka urban slum.
Two old typhoid vaccines are already prequalified by the World Health Organisation for prevention and protection from typhoid, however these are not included in the routine immunization programme of Bangladesh.
These are not licensed nor are they effective for infants and young children.
The new single-dose injectable typhoid conjugate vaccine will be used in the study. This vaccine was prequalified by the WHO in December 2017 and has been found to be safe and effective and already licensed in India and Nepal and 20,000 children have already been safely vaccinated in Nepal.
Speaking about the outcome of the study, physician Firdausi Qadri, leading the Infectious Diseases Division at icddr,b, who is also the principal investigator of the study said, ‘It is important to know the level of effectiveness of a vaccine towards a targeted population prior to scaling up nationwide.’
The study will help generating evidence about the safety profile of the vaccine and the immunogenicity as well duration of protection for Bangladeshi children, she said.
Qadri said, ‘It would also lead to impact assessment and determination of the effectiveness of the vaccine in preventing typhoid fever, hospitalizations as well as complications in children. It will also hopefully generate evidence that may lead to inclusion in the routine immunization programme.’

More about:

Want stories like this in your inbox?

Sign up to exclusive daily email

Advertisement

images

 

Advertisement

images